Total Funding
72
69
Total FundingPost-IPO Equity raised
Growth Score
-16 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10744
Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
- Mark Guerin: Chief Financial OfficerPast Role: Traws Pharma, Chief Financial Officer
Jeffrey B. McGroarty: Chief Financial OfficerPast Role: Safeguard Scientifics, SVP and CFO
About the Company
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage
AD and may stabilize the decline.
Women Founded
Women Led
